1Chua BE, Mitchell P, Cumming RG. Effects of cataract type and location on visual function:the Blue Mountains Eye Study [J]. Eye,2004,18:765-772.
2Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration:the Beaver Dam Eye Study[J]. Ophthalmology,2007,114:253-262.
3Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maeulopathy: the blue Mountains Eye Study[J]. Ophthalmology,2007,114:92-98.
4Friedman DS, O' Colmain B J, Munoz B, et al. Prevalence ofage-related macular degeneration in the United States [J]. Arch Ophthalmol,2004, 122:564-572.
5Klein R, Klein BE, Cruickshanks KJ. The prevalence of age-re- lated maculopathy by geographic region and ethnicity[J]. Prog Retin Eye Res, 1999,18:371-389.
7Libre PE. Intraoperative light toxicity: a possible explanation for the association between cataract surgery and age-related macu- lar degeneration[J]. Am J Ophthalmol,2003,136:961.
8Usui T,Ishida S,Yamashiro K,et al. VEGF164(165)as the path- ological isoform:differential leukocyte and endothelial responses through VEGFR1 and VEGFR2[J]. Invest Ophthalmol Vis Sci, 2004,45 : 368-374.
9Ursell PG, Spalton D J, Whitcup SM, et al. Cystoid macular ede- ma after phacoemulsification:relationship to blood-aqueous barri- er damage and visual acuity[J]. J Cataract Refract Surg, 1999, 25 : 1492-1497.
10Mentes J, Erakgun T, Afrashi F, et al. Incidence of cystoid mac- ular edema after uncomplicated phacoemulsification[J]. Ophthal- mologica, 2003,217 : 408-412.
二级参考文献27
1McGwin G Jr,Owsley C,Curcio CA,et al.The association between statin use and age related maculopathy.Br J Ophthalmol,2003,87:1121-1125.
2MOriF,Konno S,Hikichi T,et al.Pulsatile ocular blood flow Study: decreases in exudative age related macular degeneration.Br J Ophthalmol,2001,85:531-533.
3Gaudreault J,Fei D,Rusit J,et al.Preclinlcal pharmacokinetics of Ranibizumab(rhuFabV2) after a single intravitreal administration.Invest Ophthalmol Vis Sci,2005,46:726-733.
4Gragoudas ES,Adamis AP,Cunningham ET Jr,et al.VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.Pegaptanib for neovascular age-related macular degeneration,N Engl J Med,2004,351:2805-2816.
5Gillies MC,Simpson JM,Luo W,et al.A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration:one-year results.Arch Ophthalmol,2003,121:667-673.
6Jonas JB,Akkoyun I,Budde WM,et al.Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.Arch Ophthalmol,2004,122:218-222.
7Pratt LM,Harris A.Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.Br J Ophthalmol,2004,88:344-347.
8Markomichelakis NN,Theodossiadis PG,Sfikakis PP Regression of neovascular age-related macular degeneration following infliximab therapy Am J Ophthalmol,2005,139:537-540.
9Hawkins BS,Btessler NM,Miskala PH,et al.Submacular Surgery Trials(SST)Research Group.Surgery for subfoveal choroidal neovascularization in age-related macular degeneration:ophthalmic fmdings:SST report no.11,Ophthalmology,2004,111:1967-1980.
10Klein R,Klein BE,Linton KL.Prevalence of age-related maculopathy.The Beaver Dam Eye Study.Ophthalmology,1992,99:933-943.
